GlaxoSmithKline To Launch $13/Share Tender Offer For To Buy HGS
May 09 2012 - 2:48AM
Dow Jones News
Research-based pharmaceutical and healthcare company
GlaxoSmithKline PLC (GSK) said Wednesday it won't participate in
Human Genome Sciences Inc (HGSI) strategic alternatives review
process and will instead start a tender offer this week to buy all
of the outstanding shares of HGS for $13.00 per share in cash.
MAIN FACTS:
-GSK's offer represents a premium of 81% to HGS's closing share
price of $7.17 on April 18.
-GSK values the long relationship it has with HGS and has
clearly stated its preference to complete a transaction on a
friendly basis in a timely fashion.
-GSK remains willing to meet and review its offer with HGS at
any time.
-GSK shares closed Tuesday at 1407 pence valuing the company at
GBP71.83 billion.
-By Ian Walker, Dow Jones Newswires; 44-20-7842-9296;
ian.walker@dowjones.com
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Apr 2024 to May 2024
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From May 2023 to May 2024